Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-06-30
2009-12-22
Li, Qian Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S320100, C435S069100, C435S455000
Reexamination Certificate
active
07635468
ABSTRACT:
Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.
REFERENCES:
patent: 5681562 (1997-10-01), Sobol et al.
patent: 6039941 (2000-03-01), Blankenstein et al.
patent: 0686-697 (1995-05-01), None
patent: WO 93/06867 (1993-04-01), None
patent: WO 00/04918 (2000-02-01), None
patent: WO 01/07055 (2001-02-01), None
patent: WO 02/060476 (2002-08-01), None
patent: WO 02060476 (2002-08-01), None
patent: WO 03/031469 (2003-04-01), None
patent: WO 03/045428 (2003-06-01), None
patent: WO 03045428 (2003-06-01), None
patent: WO 2004/016786 (2004-02-01), None
Finke at al., 1997; Cancer Gene Ther. 4: 260-268.
Wittig et al., 2001, Human Gene Therapy 12: 267-278.
Sun Y. et al., 2000, Gene Therapy (17): 1467-76.
Paillard, 1998, Hum. Gene Ther. 9: 2457-2458.
Schadendorf et al., 1995, J. Mol. Med. 73: 473-477.
Jäger et al., 1996, Int J Cancer. 67(1):54-62.
Miller et al., 1993, Blood 18: 3686-3694.
Murphy et al., 1993, J. Clin. Invest. 92: 1918-1924.
Jicha et al., 1991, J. Exp. Med. 174: 1511-1515.
Hock et al., 1993, Cancer Res. 53. 714-716.
Cayeux S. et al., 1995, Eur J Immunol. Aug. 1995 25(8): 2325-31.
Schmidt-Wolf et al., 1989, J. Immunol. Methods 125: 185-189.
Sato et al., 1996, Science 273: 352-354.
Liu HM et al., Blood 1998; 92(10):3730-6.
Foa et al., 1994, Nat. Immun. 13: 65-75.
Schakowski et al., 2001, Molecular Therapy vol. 3.
Köchling Joachim et al., 2003. Clinical Cancer Research vol. 9.
Vereecque R et al., 2000, Gene Therapy 7.
Noguchi M et al., 2001, Cancer Gene Therapy, vol. 8.
Chiodoni C et al., 1999, Rockefeller U. Press vol. 190.
Dobric Tomislav
Schmidt Manuel
Wittig Burghardt
Day Ursula B.
Feiereisen Henry M.
Li Qian Janice
Mologen AG
LandOfFree
Allogeneic tumor therapeutic agent, a vaccine using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Allogeneic tumor therapeutic agent, a vaccine using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Allogeneic tumor therapeutic agent, a vaccine using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4143184